Fenbendazole as a cancer treatment

Evidence label: Preclinical findings; no verified human efficacy trials; documented serious harm · Clinical goal: assess claims that veterinary fenbendazole treats cancer

Evidence at a glance

Fenbendazole is a veterinary benzimidazole dewormer. Cell and mouse studies report microtubule and metabolic effects, but they do not establish human anticancer benefit.
No prospective human cancer efficacy trial of fenbendazole was verified in ClinicalTrials.gov or authoritative guidance during this search.
A three-patient case series circulated as human evidence was retracted in January 2026. Its reported remissions must not be treated as credible efficacy evidence.
Multiple published cases describe severe drug-induced liver injury after self-treatment; veterinary safety reporting also includes bone-marrow suppression in dogs.

What has been studied

A 2018 laboratory report found that fenbendazole had moderate microtubule-destabilizing activity, interfered with glucose uptake and affected tumor growth in cell and mouse models. These experiments did not test whether a safe human regimen improves response, recurrence or survival.

The often-cited three-patient “case series” was retracted. Uncontrolled anecdotes cannot exclude cancer therapy effects, spontaneous variability, selection bias or incomplete reporting; retraction removes even that weak report from the usable evidence base. Oxfendazole studies in healthy volunteers concern a related but different compound and do not demonstrate fenbendazole cancer benefit.

Human safety signals

Published reports describe marked hepatocellular injury after people used veterinary fenbendazole for cancer. In one 2026 report, a 47-year-old with metastatic colorectal cancer developed severe liver injury after dose escalation while receiving nivolumab and relatlimab; causality assessment rated fenbendazole a probable cause, liver tests improved after discontinuation, and immunotherapy was later resumed without recurrent injury.

Other cases, including combined fenbendazole and ivermectin use, reinforce uncertainty about dose, formulation, contamination, interactions and cumulative toxicity. Product labels and canine reports also warn of marrow hypoplasia or pancytopenia with extended veterinary use; that is not a quantified human rate but underscores that “dewormer” does not mean harmless.

Regulatory and clinical context

Fenbendazole is not FDA-approved for human use. Veterinary products are not manufactured or labeled as human oncology drugs. The FDA has challenged promotional cancer claims, and ASCO has advised against using fenbendazole or ivermectin as cancer treatments outside clinical trials.

There is no verified human dose that balances anticancer activity and safety. Online schedules that alternate “on” and “off” days are not validated regimens.

Bottom line

Fenbendazole has laboratory interest but no reliable human evidence of tumor control or survival benefit. Retraction of the only small published case series and repeated liver-injury reports shift the practical balance firmly away from self-treatment.

Questions for the care team

Could fenbendazole-related liver injury be mistaken for immunotherapy or cancer progression, and what monitoring would be needed?
What evidence supports the exact formulation, dose and interaction profile being proposed?
Is there an authoritative human trial rather than an online protocol or veterinary-product testimonial?

Sources

Literature searched: October 23, 2026 · Record appraised: October 23, 2026

Educational evidence summary, not personal medical advice. Research regimens describe what was studied; they are not personal prescribing instructions and should not replace cancer treatment or individualized supportive care.